this funding supports projects that aim to test or develop innovative approaches to:

• build capacity within the homeless serving sector, or
• eliminate or prevent homelessness in canada

description

discovery horizons grants support investigator-initiated individual and team projects that broadly integrate or transcend disciplines to advance knowledge in the natural sciences and engineering. full applications submitted to this nserc program will be reviewed by a  tri-agency interdisciplinary peer review committee.

in partnership with the canadian institutes of health research (cihr) and the social sciences and humanities research council (sshrc), nserc is piloting this new interdisciplinary peer review mechanism. the shared peer review committee will assess all full applications submitted to nserc’s discovery horizons program, as well as relevant applications submitted to sshrc’s insight grants and cihr’s project grants programs.

in the context of this funding opportunity, the term “interdisciplinary” should be understood to fully encompass all research that connects, crosses or falls in between the traditional disciplines of the three agencies, including transdisciplinary, multidisciplinary, convergence research and other approaches at the interface.

discovery horizon grants are expected to be valued from $50k–$100k per year. for this pilot year, nserc is expecting to award approximately 10–20 grants.

objectives

the discovery horizons program provides nserc’s entry-point to the tri-agency interdisciplinary peer-review mechanism. it supports discovery research projects that would significantly benefit from being assessed by a tri-agency interdisciplinary peer review committee, and aims to

1. answer natural sciences and engineering (nse) research questions that are best addressed through interdisciplinary approaches
2. advance nse disciplines through cross fertilization and new ways of thinking about research questions, ideas and frameworks; approaches and methods; platforms, tools and infrastructure; people, partners and trainees
3. provide leading-edge nse training for highly qualified personnel (hqp) in interdisciplinary research environments

the indigenous forestry initiative (ifi) provides financial support to indigenous-led economic development projects in canada’s forest sector. benefits of the program include:

• increased indigenous participation in forestry-related opportunities, businesses, careers and governance
• increased engagement and economic development for indigenous communities and peoples involved in the forest sector
• increased investment and collaboration between indigenous peoples and other natural resource development stakeholders, including governments, industry and non-governmental organizations

the fy21 defense appropriations act is anticipated to provide funding to the department of defense mbrp to support a research portfolio in the treatment of burns and the trauma associated with burn injuries sustained during combat or combat-related activities.  outcomes of successful research are anticipated to benefit service members, veterans, and the general public.  the managing agent for the anticipated program announcements/funding opportunities is the congressionally directed medical research programs (cdmrp) at the u.s. army medical research and development command (usamrdc).

fy21 mbrp program announcements and general application instructions for the following award mechanisms are posted on the grants.gov website. 

the mbrp encourages applications proposing research that advances the development or refinement of interventions, technologies, or knowledge projects that will facilitate appropriate burn care closer to the point of injury to enhance the potential for better long-term outcomes.  applications submitted to the fy21 mbrp must address the following focus area:

• complex combat-related burns:  development and/or validation of therapeutic interventions to treat military-relevant burn injury (heat, cold, chemical, or electrical) combined with other injuries including, but not limited to, hemorrhage, radiation, and/or polytrauma.  interventions or projects scalable to mass casualty events are of particular interest to the mbrp.

https://cdmrp.army.mil/funding/mbrp

clinical translational research award – preproposal due june 8, 2021

independent investigators at all academic levels (or equivalent)

• intended to support human research projects that are likely to have a major impact on patient care by applying promising and well-founded research findings to the care of the burn-injured patient, particularly at the point-of-injury, or during the acute phase of injury.
• impact is a key component of this award mechanism and should be clearly described.
• burn care interventions or projects scalable to mass casualty events are of particular interest to the mbrp.
• the proposed study must include clinical research, and may include initial proof-of- concept trials, studies involving use of human anatomical substances, observational studies, and/or involve some retrospective data analysis.
• large randomized clinical trials are discouraged.
• preliminary data is required.
• animal research is not allowed.
• pre-application submission is required; application submission is by invitation only.
• the maximum allowable funding for the entire period of performance is $1,500,000 for total costs (direct costs plus indirect costs).
• the maximum period of performance is 4 years.

idea development award – preproposal due june 8, 2021

independent investigators at all academic levels (or equivalent)

• supports highly impactful and military-relevant research in the field of burn wound care.
• inclusion of preliminary and/or published data relevant to the proposed research is required.
• research strategy and feasibility are important review criteria.
• clinical trials are not allowed.
• pre-application submission is required; application submission is by invitation only
• the maximum allowable funding for the entire period of performance is $600,000 for total costs (direct costs plus indirect costs).
• the maximum period of performance is 3 years.

a pre-application is required and must be submitted through the electronic biomedical research application portal (ebrap) at https://ebrap.org prior to the pre-application deadline.  all applications must conform to the final program announcements and general application instructions available for electronic downloading from the grants.gov website.  the application package containing the required forms for each award mechanism will also be found on grants.gov.  a listing of all cdmrp and other usamrdc extramural funding opportunities can be obtained on the grants.gov website by performing a basic search using cfda number 12.420. 

for email notification when program announcements are released, subscribe to program-specific news and updates under “email subscriptions” on the ebrap homepage at https://ebrap.org.  for more information about the mbrp or other cdmrp-administered programs, please visit the cdmrp website (https://cdmrp.army.mil).

point of contact:

cdmrp help desk
301-682-5507
help@ebrap.org

sshrc invites letters of interest from researchers wanting to participate in a virtual, interactive and interdisciplinary research design workshop taking place over two weeks at the end of october 2021.

this virtual workshop is the first stage of the imagining canada’s future (icf) ideas lab, a multistep funding opportunity. at this workshop, up to 30 researchers will participate in facilitated activities before organizing themselves into multidisciplinary teams to develop and pitch innovative project ideas. during the second stage of the icf ideas lab, teams whose partnerships and project ideas successfully met the evaluation criteria for workshop pitches will be invited to apply for funding to further develop their projects.

global challenges, such as those identified through sshrc’s imagining canada’s future initiative, are best addressed through proactive, interdisciplinary collaborations. ideas labs create new research collaborations that transcend institutional and disciplinary silos and encourage different ways of thinking, and are therefore well suited to addressing these challenges.

stage 1 of the icf ideas lab will bring together researchers from across canada to explore the theme of canada and the circular economy, linked to the global challenge of living within earth’s carrying capacity. by the end of the virtual workshop, participants will have developed preliminary proposals for groundbreaking research with the potential to inform policies and practices addressing the needs of diverse sectors throughout canada, and which can also have wider global benefits.

theme: canada and the circular economy

the canadian cancer research alliance (ccra) is seeking nominations for the 2021 ccra awards. the ccra awards, initiated in 2011, recognize and celebrate individuals who have had a remarkable impact on cancer research and the cancer research community.

learn more about ccra award nominations

to submit a nomination, please provide the nominee’s contact information and a brief overview of the reasons for nomination through the 2021 ccra awards nomination webform. nominators have the option to save their progress and complete the form at a later time. self-nominations will be accepted and are especially encouraged for individuals from equity-seeking communities. nominations are open to all, including past nominees.

nominations will remain open until may 31, 2021. should you have any questions or wish to receive further information about the ccra awards, please contact us at ccra.team@partnershipagainstcancer.ca.

the following ccra awards will be presented in 2021:

exceptional leadership in cancer research

awarded to an individual who has made exceptional contributions to fostering the development of cancer research in canada through their leadership in organizations, or development of collaborative research opportunities or initiatives that have had a transformative impact.

outstanding achievements in cancer research

awarded to a cancer researcher from any research discipline for outstanding lifetime achievements which have had an impact in greatly advancing our understanding of cancer, the treatment of cancer, and/or cancer control in canada.

distinguished service to cancer research

awarded to an individual whose work has had a substantial impact on public education, policy, or discourse on cancer control, cancer research, and/or science literacy in canada.

exceptional leadership in patient involvement in cancer research

awarded to an individual who has made exceptional contributions to fostering patient involvement in cancer research in canada. the inaugural award was presented at ccrc 2017 in vancouver.

if you are interested in being nominated for one of these awards, please contact dr. batia stolar, associate vice-president, research & graduate studies, at avp.research@lakeheadu.ca

the fy21 defense appropriations act provides funding to the department of defense neurofibromatosis research program (nfrp) to support innovative, high-impact neurofibromatosis (nf) research.  the managing agent for the anticipated program announcements/funding opportunities is the congressionally directed medical research programs (cdmrp) at the u.s. army medical research and development command (usamrdc).

the fy21 nfrp program announcements and general application instructions for the following award mechanisms are posted on the grants.gov website.   

areas of emphasis:  the nfrp encourages applications that specifically address the critical needs of the nf community in one or more of the fy21 areas of emphasis.  not all areas of emphasis are applicable to each award mechanism offered by the fy21 nfrp.  if the proposed research project does not address one of the fy21 areas of emphasis, justification that the proposed research project addresses an important problem related to nf research and/or patient care should be provided.  applications submitted to the fy21 nfrp must address one or more of the following areas of emphasis:

• biomarker discovery, utility, development, and validation
• non-tumor manifestations not limited to:

o  pain

o  cognitive manifestations

o  sleep

• heterogeneity of nf-related tumors
• novel disease and treatment response markers using genetics, genomics, epigenetics, systems biology, metabolomics, or similar approaches
• preclinical efficacy studies
• target identification, drug discovery
• nutritional, environmental, and other modifiers of nf
• health services research

https://cdmrp.army.mil/funding/nfrp

clinical trial award – letter of intent due july 8, 2021

• must be at or above the level of assistant professor
  (or equivalent).
• supports research with the potential to have a major impact on the treatment or management of nf.
• funds phase 0, 1, or 2 clinical trials relevant to nf and/or schwannomatosis.  combinations of phases are permitted.
• must support a clinical trial and may not be used for preclinical research studies.
  • the maximum period of performance is 4 years.
  • the maximum allowable funding for the entire period of performance is $800,000 in direct costs ($1,000,000 in direct costs if requesting the qualified organizational collaboration option).

• indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

exploration – hypothesis development award – letter of intent due july 8, 2021

• investigators at all academic levels (or equivalent).
• supports the initial exploration of innovative, high-risk, high-gain concepts and potentially groundbreaking concepts in nf research.
• preliminary and/or published data are encouraged but not required.
• clinical trials are not allowed
• the maximum period of performance is 2 years.
• the maximum allowable funding for the entire period of performance is $100,000 in direct costs.
• indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

investigator-initiated research award – letter of intent due july 8, 2021

must be an investigator at or above the level of assistant professor (or equivalent) who plans to commit at least a 10% level of effort for each budget period for the entirety of the award.

• supports highly rigorous, high-impact research with the potential to make an important contribution to nf research and/or patient care.
• preliminary and/or published data relevant to nf are required.
• optional features: applications meeting criteria identified in the program announcement may apply for a higher level of funding for the following options: qualified collaborator and/or nf open science initiative (nf-osi).
• clinical trials are not allowed.
• the maximum period of performance is 3 years.
• the maximum allowable funding for the entire period of performance is $525,000 in direct costs.
• the maximum allowable funding for applications including either the optional qualified collaborator or the nf‑osi option is $575,000 in direct costs.
• the maximum allowable funding for applications including both the optional qualified collaborator option and the nf-osi option is $625,000 in direct costs.
• indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

early investigator research award – letter of intent due july 8, 2021

the investigator must:

• be involved in a postdoctoral training or medical residency program; and
• possess at least 1 and up to 4 years of continuous postdoctoral research experience by application submission deadline; and
• possess a doctoral degree (i.e., ph.d., m.d./ph.d., d.o./ph.d.) or a clinical doctoral degree (i.e., m.d./d.o. or ph.d. in a clinical discipline) from an accredited organization or program.
  • supports nf-focused research opportunities for individuals in the early stages of their careers.
  • investigators must have a designated mentor who is an experienced nf researcher.
  • the maximum period of performance is 2 years.
  • the maximum allowable funding for the entire period of performance is $200,000 in direct costs.
  • indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

synergistic idea development award – letter of intent due july 8, 2021

must be an investigator at or above the level of assistant professor (or equivalent) who plans to commit at least a 10% level of effort for each budget period throughout the entirety of the award.

• supports new ideas that represent synergistic approaches involving two or three principal investigators (pis) (initiating pis and pi[s]) to address a central problem or question in nf research.
• preliminary and/or published data are required.
• clinical trials are not allowed.
• the maximum period of performance is 3 years.
• the maximum allowable funding for the entire period of performance is $200,000,000 in direct costs.

a pre-application is required and must be submitted through the electronic biomedical research application portal (ebrap) at https://ebrap.org prior to the pre-application deadline.  all applications must conform to the final program announcements and general application instructions that will be available for electronic downloading from the grants.gov website.  the application package containing the required forms for each award mechanism will also be found on grants.gov.  a listing of all cdmrp and other usamrdc extramural funding opportunities can be obtained on the grants.gov website by performing a basic search using cfda number 12.420. 

for email notification when program announcements are released, subscribe to program-specific news and updates under “email subscriptions” on the ebrap homepage at https://ebrap.org.  for more information about the nfrp or other cdmrp-administered programs, please visit the cdmrp website (https://cdmrp.army.mil).

point of contact:

cdmrp help desk
301-682-5507
help@ebrap.org

the ams doctoral completion award provides funding to doctoral 世界杯2022赛程表淘汰赛 to help support full-time dissertation writing leading to dissertation completion in the humanities or social sciences, writing on a history of medicine/health care topic – broadly defined as the study of past practices and epistemologies related to human health, healthcare, and disease.